Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum
- 1 November 1995
- journal article
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 19 (7) , 1147-1154
- https://doi.org/10.1016/0278-5846(95)00232-4
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralinBrain Research, 1994
- Current Status of Dopamine Agonists in Parkinson??s Disease ManagementDrugs, 1993
- Dopamine D3 receptor mRNA and binding sites in human brainMolecular Brain Research, 1993
- Dopamine Agonist Treatment of Fluctuating ParkinsonismArchives of Neurology, 1992
- Effect of LY 171555 and CY 208‐243 on tremor suppression in the MPTP monkey model of parkinsonismMovement Disorders, 1992
- In Human Brain Two Subtypes of D1 Dopamine Receptors Can Be Distinguished on the Basis of Differences in Guanine Nucleotide Effect on Agonist BindingJournal of Neurochemistry, 1989
- D2 dopamine receptors in the human brain: heterogeneity based on differences in guanine nucleotide effect on agonist binding, and their presence on corticostriatal nerve terminalsBrain Research, 1989
- Clinical Importance of D-1 and D-2 ReceptorsCanadian Journal of Neurological Sciences, 1987
- Comparison of pergolide and bromocriptine therapy in parkinsonismNeurology, 1983
- Species variations in dopamine receptor bindingEuropean Journal of Pharmacology, 1979